Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSV | O60911 | 4/20 | 0.48 |
| ▸ | CTSL | P07711 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | EDNRA | P25101 | 1/20 | 0.43 |
| ▸ | MYC | P01106 | 1/20 | 0.43 |
| ▸ | MAX | P61244 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.40 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.40 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.40 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17775441 | 0.90 | MEN1 (0.47) | CTSVCTSLMEN1KMT2AEDNRA | |
| SCHEMBL28511094 | 0.85 | MYC (0.51) | CTSVCTSLMEN1KMT2AEDNRA | |
| SCHEMBL17795680 | 0.85 | ALDH1A1 (0.46) | KMT2AL3MBTL1TDP1 | |
| SCHEMBL527106 | 0.83 | CTSV (0.52) | CTSVCTSLMEN1KMT2AMAPT | |
| SCHEMBL16392499 | 0.82 | AKR1C3 (0.45) | KMT2AMAPTPOLBTDP1LMNA | |
| SCHEMBL23190746 | 0.81 | MCL1 (0.48) | EDNRAMAPTL3MBTL1TDP1GLRA1 | |
| SCHEMBL16369635 | 0.81 | MYC (0.62) | CTSVCTSLMEN1KMT2AMYC | |
| SCHEMBL20764495 | 0.81 | TSHR (0.37) | KMT2AL3MBTL1POLBTDP1 | |
| SCHEMBL3093865 | 0.81 | CTSV (0.58) | CTSVCTSLMEN1KMT2AL3MBTL1 | |
| SCHEMBL20764575 | 0.79 | MEN1 (0.49) | CTSVCTSLMEN1KMT2AMYC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110997627-B | Cyst amide derivatives | 亥姆霍兹感染研究中心有限公司 | 2023-10-10 | — | — | CN | disclosed |
| US-11225503-B2 | Crystobactamides | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2022-01-18 | — | — | US | disclosed |
| US-11225503-B2 | Crystobactamides | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2022-01-18 | — | — | US | disclosed |
| US-11034648-B2 | Cystobactamide derivatives | HELMHOLTZ-ZENTRUM FÜR (DE) | 2021-06-15 | — | — | US | disclosed |
| US-11034648-B2 | Cystobactamide derivatives | HELMHOLTZ-ZENTRUM FÜR (DE) | 2021-06-15 | — | — | US | disclosed |
| EP-3019615-B1 | CYSTOBACTAMIDES | HELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH (DE) | 2021-04-07 | — | — | EP | disclosed |
| EP-3019615-B1 | CYSTOBACTAMIDES | HELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH (DE) | 2021-04-07 | — | — | EP | disclosed |
| CN-105793424-B | Ascomycetes amides | 亥姆霍兹感染研究中心有限公司 | 2021-02-19 | — | — | CN | disclosed |
| US-20200331964-A1 | CYSTOBACTAMIDES | HELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH (DE) | 2020-10-22 | — | — | US | disclosed |
| US-20200331964-A1 | CYSTOBACTAMIDES | HELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH (DE) | 2020-10-22 | — | — | US | disclosed |
| US-20200190020-A1 | NOVEL CYSTOBACTAMIDE DERIVATIVES | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2020-06-18 | — | — | US | disclosed |
| CN-110997627-A | Novel cystobacter amide derivatives | 亥姆霍兹感染研究中心有限公司 | 2020-04-10 | — | — | CN | disclosed |
| US-20190185514-A1 | CYSTOBACTAMIDES | HELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH (DE) | 2019-06-20 | — | — | US | disclosed |
| US-20190185514-A1 | CYSTOBACTAMIDES | HELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH (DE) | 2019-06-20 | — | — | US | disclosed |
| WO-2019038405-A1 | NOVEL CYSTOBACTAMIDE DERIVATIVES | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2019-02-28 | — | — | WO | disclosed |
| CN-105793424-A | Ascomycetes amides | 亥姆霍兹感染研究中心有限公司 | 2016-07-20 | — | — | CN | disclosed |
| US-20160145304-A1 | CYSTOBACTAMIDES | HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH (DE) | 2016-05-26 | — | — | US | disclosed |
| US-20160145304-A1 | CYSTOBACTAMIDES | HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH (DE) | 2016-05-26 | — | — | US | disclosed |
| EP-3019615-A2 | CYSTOBACTAMIDES | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2016-05-18 | — | — | EP | disclosed |
| WO-2015003816-A2 | CYSTOBACTAMIDES | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2015-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11034648-B2 | Cystobactamide derivatives | CTH, CBS, SLC7A11 | CTSV 975/4885CTSL 189/4885MEN1 2023/4885 |
| US-20160145304-A1 | CYSTOBACTAMIDES | CTH, SLC7A11, CBS | CTSV 483/4885CTSL 116/4885MEN1 1314/4885 |
| US-11225503-B2 | Crystobactamides | PKD2, SLC7A11, CTH | CTSV 555/4885CTSL 220/4885MEN1 1524/4885 |
| US-20190185514-A1 | CYSTOBACTAMIDES | CTH, SLC7A11, SULT2A1 | CTSV 647/4885CTSL 244/4885MEN1 1050/4885 |
| US-20200190020-A1 | NOVEL CYSTOBACTAMIDE DERIVATIVES | CTH, CBS, SLC7A11 | CTSV 942/4885CTSL 192/4885MEN1 2097/4885 |
| US-20200331964-A1 | CYSTOBACTAMIDES | CTH, SLC7A11, SULT2A1 | CTSV 687/4885CTSL 222/4885MEN1 1286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.